Our research into anti-CD30 antibodies begins.
Our scientists synthesize monomethyl auristatin E (MMAE), the cytotoxic drug payload for our first antibody–drug conjugate (ADC), brentuximab vedotin (ADCETRIS®).
The first patient is treated with ADCETRIS.
Seagen and Agensys (acquired by Astellas) enter into a collaboration, resulting in the co-development of enfortumab vedotin, an ADC that targets Nectin-4.
Seagen and Takeda agree to globally co-develop and commercialize ADCETRIS.
ADCETRIS® (brentuximab vedotin) is approved in the U.S. for relapsed classical Hodgkin lymphoma (cHL) and relapsed systemic anaplastic large cell lymphoma (ALCL).
ADCETRIS is approved in the European Union for certain patients with classical Hodgkin lymphoma (cHL).
Seagen expands access to ADC technology via collaborations with global biotechnology and pharmaceutical industry leaders.
Our European headquarters opens in Zug, Switzerland.
ADCETRIS is approved in the U.S. for primary cutaneous ALCL or CD30-expressing mycosis fungoides, the most common type of cutaneous T-cell lymphoma (CTCL).
20-year anniversary of Seagen.
ADCETRIS is approved in the U.S. in combination with chemotherapy for previously untreated stage 3 or 4 cHL.
ADCETRIS is approved in the U.S. in combination with chemotherapy for previously untreated sALCL or other CD30-expressing peripheral T-cell lymphomas (PTCL).
Seagen acquires Cascadian Therapeutics, including the late-stage investigational agent tucatinib.
PADCEV® (enfortumab vedotin-ejfv) is approved in the U.S. to treat certain types of metastatic urothelial cancers post PD(L)-1 inhibitor and a platinum-containing chemotherapy.
ADCETRIS is established as a foundation of care for certain types of CD30-expressing lymphomas and approved in more than 70 countries.
TUKYSA® (tucatinib) is approved in the U.S. and other countries for certain HER2+ metastatic breast cancers in combination with trastuzumab and capecitabine -- our third approved and first wholly-owned medicine.
Seattle Genetics, Inc. changes its name to Seagen Inc. to reflect the transformation of the company from its strong Seattle roots into a global operation.
TIVDAK™ (tisotumab vedotin-tftv) is approved in the U.S. for previously treated recurrent or metastatic cervical cancer – our fourth approved medicine.
Our commitment to innovation and making a meaningful impact in cancer care continues.